Trial · NCT02909088
Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering).
NCT02909088, Phase 2, Phase 3, Unknown, Gerald Maguire, MD
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering). Trials, record NCT02909088. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02909088
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering).
- NCT number
- NCT02909088
- Status
- Unknown
- Phases
- Phase 2, Phase 3
- Enrollment
- 10 participants, estimated
- Lead sponsor
- Gerald Maguire, MD
- Conditions
- Stuttering, Adult, Childhood-onset Fluency Disorder, Speech Disorders, Language Disorders, Communication Disorder
- Interventions
- Ecopipam 50mg, Ecopipam 100mg
- First posted
- 2016-09-21
- Last updated
- 2016-10-26
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in the Stuttering Severity Instrument Version IV (SSI-IV) | This scale is completed on Visit 1/screening and Visit 5/week 8. | This is an objective measure of stuttering in which it captures verbal samples of five minutes speaking during a conversation and 5 minutes of reading a passage. |
| Secondary | Clinical Global Impression Scale-Severity (CGI-S) | This scale is completed on Visit 1/screening, Visit 2/baseline, Visit 3/week 2, and Visit 5/week 8. | This is an evaluation of the patient by the investigator as to whether or not the subjects has improved, remained the same, or worsened while in the study. |
| Secondary | Subjective Stuttering Scale (SSS) | This scale is completed on Visit 2/baseline and Visit 5/week 8. | |
| Secondary | Overall Assessment of the Speaker's Experience of Stuttering (OASES) | This scale is completed on Visit 2/baseline and Visit 5/week 8. | |
| Secondary | Montgomery Asberg Depression Rating Scale (MADRS) | This scale is completed on Visit 2/baseline, Visit 3/week 2, Visit 4/week 4 and Visit 5/week 8. | An observer-rated depression scale |
| Secondary | Barnes Akathisia Scale (BAS) | This scale is completed on Visit 1/screening, Visit 5/week 8. | measures how restless the subject is during the examination |
| Secondary | Abnormal Involuntary Movement Scale (AIMS) | This scale is completed on Visit 1/screening, Visit 5/week 8. | |
| Secondary | Columbia-Suicide Severity Rating Scale (C-SSRS) | This scale is completed on Visit 1/screening, Visit 2/baseline, Visit 3/week 2, Visit 4/week 4 and Visit 5/week 8. | |
| Secondary | Simpson Angus Scale (SAS) | This scale is completed on Visit 1/screening, Visit 5/week 8. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers7
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02909088
GET https://conductscience.org/api/trials/v1/NCT02909088/registered